Aerami Therapeutics Holdings and FoxWayne Enterprises Acquisition announced that they have mutually agreed to terminate their previously announced business combination agreement.
The companies cited “current unfavorable market conditions” for the decision. Announced in December, the deal was expected to provide Aerami with up to $250 million.
FoxWayne has until April 22 to complete a deal unless the deadline is extended by another three months with a cash infusion of 2.5 cents per share into the trust account.
Aerami is a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases. Read more.
